Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19299281 | 0.95 | BACE1 (0.32) | PDK2BACE1NPC1MAPTPKM | |
| SCHEMBL21677689 | 0.93 | SMARCA2 (0.33) | PDK2ENPP3BACE1NPC1MAPT | |
| SCHEMBL21677479 | 0.91 | BACE1 (0.31) | BACE1NPC1MAPTPKMMAOB | |
| SCHEMBL20619783 | 0.89 | PDK2 (0.38) | PDK2ENPP3BACE1NPC1MAPT | |
| SCHEMBL19298386 | 0.89 | NPC1 (0.33) | NPC1MAPTPKMMAOBAGTR1 | |
| SCHEMBL20619115 | 0.88 | MAPT (0.37) | PDK2ENPP3BACE1MAPTAGTR1 | |
| SCHEMBL21677730 | 0.88 | PDK2 (0.37) | PDK2ENPP3BACE1NPC1MAPT | |
| SCHEMBL21677848 | 0.87 | MEN1 (0.40) | PDK2ENPP3BACE1MAPTMAOB | |
| SCHEMBL21677525 | 0.87 | MAPT (0.38) | PDK2ENPP3BACE1MAPTMAOB | |
| SCHEMBL21677470 | 0.87 | MAPT (0.38) | PDK2ENPP3BACE1MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024114-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20220376178-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2022-11-24 | — | — | US | disclosed |
| US-11152576-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20210288264-A1 | Heterocyclic Compound And Organic Light Emitting Element Comprising Same | LG CHEM, LTD. (KR) | 2021-09-16 | — | — | US | disclosed |
| US-11094889-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. | 2021-08-17 | — | — | US | disclosed |
| US-20210013422-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2021-01-14 | — | — | US | disclosed |
| US-20200365814-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2020-11-19 | — | — | US | disclosed |
| US-20200035930-A1 | ORGANIC LIGHT EMITTING ELEMENT | LG CHEM, LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210288264-A1 | Heterocyclic Compound And Organic Light Emitting Element Comprising Same | CRY1, CRY2, PER2 | PDK2 2812/4885ENPP3 2206/4885BACE1 616/4885 |
| US-11094889-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | PDK2 2812/4885ENPP3 2206/4885BACE1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.